Newly Spun Off from Integra Life Sciences, SeaSpine Adds to its Leadership Ranks

Vista, Calif.-based SeaSpine Holdings Corp. has added to its management team. The company recently went public as a spinoff from N.J.-based Intergra LifeSciences.

Tyler Lipschultz has been named vice president, orthobiologics and business development. Lipschultz will be responsible for orthobiologics marketing and development, as well as business development for all of SeaSpine. He has more than 25 years of sales, marketing, and operational leadership experience in spine and general orthopedic devices. Most recently, he served as executive vice president of NuVasive Inc., including four years leading global operations and prior, leading the biologics organization. Over the course of his career, Lipschultz also has held global management roles at Spine Wave Inc., VERTx, DePuy Synthes, Smith & Nephew plc, and Stryker Corp. He also has served as an equity research analyst for Piper Jaffray, where he focused his research on orthopedic and spinal markets.

Laetitia Cousin has been named vice president, regulatory, clinical and quality assurance. Cousin has nearly two decades of medical technology experience, primarily in regulatory affairs and quality assurance. For the past 16 years, she has held progressively senior positions at NuVasive. Most recently, she served as vice president, regulatory and clinical affairs, quality assurance. The new hires will be part of the senior leadership team reporting directly to Keith Valentine, president and CEO.

“We are pleased to welcome Tyler and Laety to SeaSpine,” said Valentine. “SeaSpine is assembling an exceptionally qualified management team with deep experience in spine and in broader medical technology. Our goal is to effectively scale our business and advance our market position in orthobiologics and spine implants through targeted investment and strong execution. These key management appointments are a testament to our commitment to achieving that goal. We look forward to leveraging our expanding leadership team’s experience as we reposition for growth as an independent public company.”

SeaSpine’s orthobiologics products consist of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal fusion hardware portfolio consists of products to facilitate spinal fusion in minimally invasive surgery, complex spine, deformity and degenerative procedures.